Business Wire

Kongsberg Precision Cutting Systems Acquires MultiCam

23.8.2021 09:00:00 EEST | Business Wire | Press release

Share

OpenGate Capital, a global private equity firm, announced today that its portfolio company, Kongsberg Precision Cutting Systems (“Kongsberg PCS”) has acquired MultiCam, a U.S. manufacturer and distributor of Computer Numerical Code (“CNC”) cutting machines, and a leader in digital finishing processes. MultiCam was acquired from Rosewood Private Investments. Terms of the acquisition were not disclosed.

The acquisition of MultiCam highlights OpenGate Capital’s strategy of pursuing add-on investments as means of growing and creating meaningful value in its portfolio companies. MultiCam is the seventh add-on investment completed for platform companies within OpenGate’s Fund II portfolio.

Kongsberg PCS is recognized as the leading provider of high-speed, precision cutting systems for packaging, signage, and display purposes, and has operational facilities in Belgium, Czech Republic, and Norway serving markets in Europe, the Americas, and Asia. The acquisition of MultiCam, including its operations in the U.S. and sales offices in Canada and Germany, expands Kongsberg PCS’ market reach and customer base across North America and Europe, and creates the world’s first, diversified provider of CNC cutting machines.

OpenGate Capital’s Partner, Julien Lagrèze stated, “Prior to our acquisition of Kongsberg PCS, which was completed just five months ago, we recognized the importance of digitization for this business and developed an investment thesis that includes the growth of Kongsberg PCS through innovation and add-on investments. With this strategic combination, Kongsberg PCS gains greater scale, and expands its reach to a broader, global customer base with new products and services.”

OpenGate’s investment team recognizes the importance of industrial automation for Kongsberg PCS and many of its investments considering the current state of labor shortages, the impact of the pandemic, and a goal to drive sustainability across the firm’s portfolio of companies. Industrial digitization also benefits OpenGate’s investments through greater transparency, supply chain analysis, manufacturing improvements, and greater ability to flex with market changes. Kongsberg, with MultiCam, represents the heart of industrial automation, driving change through the expanded services they offer.

MultiCam will continue to operate under the same name within Kongsberg PCS, with Chief Executive Officer David Morse joining Kongsberg’s senior management team and continuing to lead the MultiCam business.

Founded in 1989, MultiCam has a global installed base of over 14,000 tables and is uniquely positioned through its three primary cutting technologies of routers, digital finishing, and waterjet, plasma, and laser fabrications. MultiCam has approximately 130 employees serving customers across a large range of verticals including industrials, manufacturing, packaging, and signage and display.

Kongsberg PCS President, Stuart Fox commented, “This is a monumental day for Kongsberg and MultiCam as it represents a tremendous advantage for our businesses coming together to drive best-in-class cutting and finishing processes for our global customer base. I am excited to begin our work, integrate our businesses, and explore new markets.”

About OpenGate Capital

OpenGate Capital is a global private equity firm specializing in the acquisition and operation of businesses to create new value through operational improvements, innovation, and growth. Established in 2005, OpenGate Capital is headquartered in Los Angeles, California with a European office in Paris, France. OpenGate’s professionals possess the critical skills needed to acquire, transition, operate, build, and scale successful businesses. To date, OpenGate Capital, through its legacy and fund investments, has executed more than 30 acquisitions including corporate carve-outs, management buyouts, special situations, and transactions with private sellers across North America and Europe. To learn more about OpenGate, please visit www.opengatecapital.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

OpenGate Media Contacts
Prosek Partners
Email: Pro-opengate@prosek.com

Alanna Chaffin
Co-Head, Investor Relations & Communications
Email: AChaffin@opengatecapital.com
Telephone: +1 310-432-7000

OpenGate Business Development Contact
Joshua Adams
Email: jadams@opengatecapital.com
Telephone: +1 (310) 432-7000

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye